# Phase I/II Trial of Stereotactic Body Radiotherapy With Concurrent Fixed Dose Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma: Dose Limiting Toxicity and Abscopal Effect.

> **NCT02334709** · PHASE1,PHASE2 · COMPLETED · sponsor: **University Hospital, Ghent** · enrollment: 13 (actual)

## Conditions studied

- Carcinoma, Renal Cell

## Interventions

- **RADIATION:** Stereotactic body radiotherapy

## Key facts

- **NCT ID:** NCT02334709
- **Lead sponsor:** University Hospital, Ghent
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2017-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02334709

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02334709, "Phase I/II Trial of Stereotactic Body Radiotherapy With Concurrent Fixed Dose Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma: Dose Limiting Toxicity and Abscopal Effect.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02334709. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*